El uso de IA está contribuyendo a descubrir nuevos medicamentos así como a mejorar la precisión y la velocidad del diagnóstico, personalizar los tratamientos y automatizar tareas administrativas.
Artificial intelligence (AI) is starting to be used to speed up clinical trials and help discover new drugs, as highlighted by experts who participated in the 34th National Assembly of the Pharmaceutical Research and Marketing Association (AIMFA).
According to the association in a press release, during the working sessions held in Zaragoza, the researchers highlighted how AI applications in industry are already a reality and are transforming the healthcare sector worldwide.
AI applications are a reality and are transforming the healthcare sector worldwide.
More than 140 specialists in new technologies in healthcare have addressed how AI is being used to improve the accuracy and speed of diagnosis, personalize treatments and automate administrative tasks, allowing medical professionals to focus on the needs of patients.
In this regard, the head of Digital Transformation at Gebro Pharma, Ricard Castellet, explained that AI systems “can analyze large amounts of data faster and more accurately than humans, which can help to identify new treatment targets and design more effective drug molecules.”
“The most efficient healthcare organizations will be those that are able to integrate AI into their day-to-day work, with the patient as the driving force transforming the sector,” added this specialist.
Efficient uses of AI in healthcare
At the AIMFA Assembly, several successful cases of the application of artificial intelligence in the healthcare sector were presented, both for the hospital setting and to improve production and sales.
In this sense, attendees had the opportunity to learn about programs to improve patient-centered healthcare marketing, which collect more useful and personalized data and therapeutic exercises guided by AI.
Thus, a specialist from Sanofi, Andreu Robusté, presented ‘Turing’, an AI program that allows to assign to each client a mix of channels, contacts and contents adapted to their response and preferences, while Carla de la Roja, from Novartis, unveiled ‘Next Best Action’, another AI tool that allows to predict the most effective action a salesperson should take to interact with a doctor.
In addition, the founder of Telómera, José Luis Enríquez, presented cost-efficient uses of AI in emergency services, in ICUs and in the analysis of medical images.
In his opinion, “in healthcare, AI should not focus on saving labor costs for healthcare systems, but should improve the quality of life of patients and physicians. It should help to extend the capabilities of physicians and contribute to reducing indirect costs.”
Source: Heraldo de Aragón.
|
Subscripción via RSS |
·